Cancer Drug Endpoints: ctDNA Promising But Presents Many Challenges, Experts Say

 
• By Sue Sutter

To validate change in circulating tumor DNA as an early endpoint predictive of longer-term outcomes, academia, industry and regulators must harmonize data collection for trials in early-stage disease, a Friends of Cancer Research white paper states.

Long road
The road to establishing ctDNA as predictive of long-term outcomes in early-stage disease is a long one. • Source: Alamy

More from Clinical Trials

More from R&D